Trial Profile
A Randomized, Double-Blind, Parallel-Group, 12-Week, Chronic Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Aug 2018
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 17 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 May 2017 Planned End Date changed from 7 Dec 2017 to 7 Dec 2018.
- 31 May 2017 Planned primary completion date changed from 7 Dec 2017 to 7 Dec 2018.